What’s New In Childhood Vaccines

PAMELA ROCKWELL, DO, University of Michigan Family Medicine, Ann Arbor, Michigan

See related Practice Guideline on page 229.

Recommending and providing childhood vaccines is a vital part of a family physician’s role in delivering health care to our youth. This editorial reviews several changes in childhood vaccines in the past two years (Table 1).

In 2013, the Advisory Committee on Immunization Practices (ACIP) recommended combining the immunization schedules for children six years and younger and for children seven through 18 years of age into one schedule for all children from birth through 18 years of age. Printable versions of this document with regular and catch-up schedules are available at http://www.cdc.gov/vaccines/schedules.

This new easy-to-read schedule illustrates the 2011 ACIP recommendation that boys 11 to 12 years of age should routinely receive the quadrivalent human papillomavirus (HPV) vaccine in a three-dose series; the series can start as early as nine years of age. The vaccine is also routinely recommended for men 22 to 26 years of age who are immunocompromised, including those with human immunodeficiency virus infection, and for men who have sex with men. This vaccine covers HPV strains 16 and 18, which are responsible for about 70% of cervical and other genital cancers and many oropharyngeal cancers; and strains 6 and 11, which are known to be largely responsible for most genital warts and recurrent respiratory papillomatosis. HPV is increasingly linked to head and neck cancers, and males are at higher risk than females.¹ We should remind ourselves, and our patients, that in targeting HPV, vaccination prevents cancer. For parents concerned about how the vaccine affects sexual behavior, research has shown that there is no increase in sexual activity in girls 11 to 12 years of age followed over four years after receiving the HPV vaccination.²

Another 2011 ACIP recommendation updates the contraindications for the rotavirus vaccine: a history of intussusception, formerly a precaution, is now cited as an absolute contraindication to vaccination. For all others without a history of intussusception, there is a small overall excess risk of approximately 0.79 intussusception.

### Table 1. New Recommendations for Childhood Vaccines from the Advisory Committee on Immunization Practices

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Previous recommendation</th>
<th>Change since 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human papillomavirus</td>
<td>Routinely advised only for girls 11 to 12 years of age</td>
<td>Routinely advised for boys 11 to 12 years of age (range: 9 to 21 years of age and men 22 to 26 years of age* who are immunocompromised, have HIV infection, or who have sex with men)</td>
</tr>
<tr>
<td>Meningococcal</td>
<td>Routine vaccination of adolescents at 11 to 12 years of age; no booster recommended</td>
<td>Booster recommended at 16 years of age (up to 18 years of age) if immunization given before 16 years of age</td>
</tr>
<tr>
<td></td>
<td>Routine single-dose vaccination of children with increased susceptibility†</td>
<td>Routine two-dose primary series administered two months apart for persons two to 54 years of age with increased susceptibility†</td>
</tr>
<tr>
<td></td>
<td>No routine vaccination of adolescents with HIV infection</td>
<td>Routine two-dose primary series administered two months apart for adolescents with HIV infection</td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>May be used in children six to 18 years of age with immunocompromising conditions</td>
<td>Routine use recommended for children six to 18 years of age with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants</td>
</tr>
<tr>
<td>Rotavirus</td>
<td>History of intussusception is a relative contraindication to the vaccine</td>
<td>History of intussusception is an absolute contraindication to the vaccine</td>
</tr>
</tbody>
</table>

HIV = human immunodeficiency virus.

*—May complete second and third doses after 27 years of age if first dose given at or before 26 years of age.
†—Includes persons with persistent complement component deficiency (e.g., C5 to C9, properdin, factor H, or factor D) and functional or anatomic asplenia.
Editorials

events for every 100,000 vaccinated infants. This translates to 33 excess intussusception events annually in the United States after rotavirus vaccination. When compared with the 40,000 hospitalizations prevented annually since the rotavirus vaccine was introduced, it appears to be a small and acceptable public health risk.

Also in the past two years, ACIP made two new recommendations concerning quadrivalent meningococcal conjugate vaccines: (1) routine vaccination of adolescents at 11 or 12 years of age with a booster dose at 16 years of age (up to 18 years of age); and (2) a two-dose primary series administered two months apart for persons two through 54 years of age with persistent complement component deficiency (e.g., C5 to C9, properdin, factor H, or factor D) and functional or anatomic asplenia, and for adolescents with human immunodeficiency virus infection.

ACIP also recommends routine use of the 13-valent pneumococcal conjugate vaccine for children six to 18 years of age with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants who have not previously received the vaccine. These children should receive the 13-valent pneumococcal conjugate vaccine regardless of whether they received the 7-valent pneumococcal conjugate vaccine or the 23-valent pneumococcal polysaccharide vaccine.

Address correspondence to Pamela Rockwell, DO, at prockwel@med.umich.edu. Reprints are not available from the author.

Author disclosure: No relevant financial affiliations.

REFERENCES


AFP Directory

Article proposals—Contact Jay Siwek, MD, editor (e-mail: afpjournal@aafp.org).

Other editorial questions—Call 913-906-6205 or send a fax to 913-906-6086. Use the list below to find the person who can best help you:

• Reader feedback—Contact Joyce A. Merriman, executive editor (e-mail: afpedit@aafp.org). For letters to the editor, follow the instructions on the first page of “Letters to the Editor” in each issue or in the Authors’ Guide at http://www.aafp.org/afp/authors.

• Delivery problems, back issues—Contact the circulation department (800-274-2237; e-mail: afpcirc@aafp.org).

• Subscriptions, address changes—Refer to the ordering information on the first page of the table of contents, in the left-hand margin. For address changes: submit the change of address form provided in this issue (refer to the table of contents listing for the location of the form).

• Permission to reuse material from AFP:

  Academic use, general photocopying, electronic use—See www.copyright.com and enter ISSN 0002-838X in the search box; or contact the Copyright Clearance Center (info@copyright.com; 978-750-8400; fax: 978-646-8700).
  Bulk reprints, e-prints—Contact Beth Ann Rocheleau, Rockwater, Inc. (brocheleau@rockwaterinc.com; 803-359-4578).
  Other requests—Contact AAFP intellectual property coordinator (copyrights@aafp.org).

Display advertising—Contact John Molluso, director of advertising sales (e-mail: jmolluso@aafp.org), or Mickey Cotter, national account manager (e-mail: mcotter@aafp.org); telephone: 201-288-4440; fax: 201-288-4914.

Classified information—Contact Russell Johns Associates, LLC (telephone: 800-237-7027; fax: 727-445-9380; e-mail: afpinfo@russelljohns.com).

Editorial Policies

The purpose of AFP is to serve the medical profession and provide continuing medical education (CME). The information and opinions presented in AFP reflect the views of the authors, not those of the journal or the American Academy of Family Physicians, unless so stated. Advertising is accepted only if judged to be in harmony with the purpose of the journal; however, AFP reserves the right to reject any advertising at its sole discretion. Acceptance does not constitute endorsement by AFP or the American Academy of Family Physicians of a particular policy, product, procedure, or adverterial.

It is the policy of the American Academy of Family Physicians that all individuals in a position to affect the content of a CME activity disclose relationships that they or their spouse/partner have with commercial entities. Further, should any such relationship be determined to be in possible conflict of interest as it relates to the individual’s proposed role in the CME activity, the conflicts of interest must be resolved before confirmation of the individual’s participation. We inform readers of any pertinent relationships disclosed. A disclosure statement is published at the end of relevant articles. The medical and professional editors of AFP have disclosed all relationships with commercial interests. There are no relevant conflicts of interest to disclose.

AFP publishes trade names of drugs for the readers’ convenience only; published names are based on what is currently available. This does not imply endorsement of any product by AFP or the American Academy of Family Physicians.

CME Objectives

1. To provide updates on the diagnosis and treatment of clinical conditions managed by family physicians.

2. To provide reference citations to support statements referring to clinical studies, new information, controversial material, specific quantitative data, and any other information not generally found in reference textbooks on the subject.

3. To provide balanced discussions of the strengths and weaknesses of diagnostic and treatment strategies (controversial or speculative material is identified).

4. To provide evidence-based guidelines or consensus viewpoint in preference to personal opinion.